Searchable abstracts of presentations at key conferences in endocrinology

ea0063p247 | Pituitary and Neuroendocrinology 1 | ECE2019

MRI follow-up is not useful in patients with GH-secreting pituitary adenomas primarily treated and responsive to long-acting somatostatin analogs (SMSa)

Grandgeorge Naia , Barchetti Giovanni , Grunenwald Solange , Bonneville Fabrice , Caron Philippe

Introduction: Primary SMSa treatment can be associated with hormonal remission and tumor shrinkage in patients with GH-secreting pituitary adenomas. In the 2014 Endocrine Society guideline for Acromegaly, there is no specific mention of MRI follow-up during long-term SMSa treatment. The aim of this study was to evaluate any change of GH-secreting adenoma size during primary SMSa treatment and whether regular MRI follow-up was necessary in acromegalic patients treated with firs...

ea0070aep759 | Pituitary and Neuroendocrinology | ECE2020

MRI follow-up of patients with acromegaly treated with first-generation somatostatin analogues (SMSa): Is there a difference during primary or post-operative treatment?

Naia Grandgeorge , Giovanni Barchetti , Solange Grunenwald , Fabrice Bonneville , Caron Philippe

Objectives: First-generation SMSa are the medical treatment of choice in the management of acromegaly, mainly as adjuvant treatment of pituitary surgery when normal IGF-1 is not obtained or as primary treatment in selected patients. The main objective of this study is to evaluate regular pituitary MRI follow-up of acromegalic patients treated with SMSa as adjuvant treatment of pituitary surgery. The secondary objective is to compare the anti-tumoral effect of SMSa in post-oper...